This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Neuroglee Therapeutics , a startup developing digitaltherapeutics for people with neurodegenerative diseases, has raised a $10 million Series A led by Openspace Ventures and EDBI. The funding will be used to launch virtual neurology clinics and to support Neuroglee’s move to Boston. Neuroglee gets $2.3
We’re excited to share that metaMe Health , a prescription digitaltherapeutics (PDT) company, today announced raising $2.2M We are thrilled to have the support of HPA as we prepare for the launch of Regulora,” said Tim Rudolphi, CEO of metaMe Health. “We in funding.
We’re excited to share that metaMe Health , a prescription digitaltherapeutics (PDT) company, today announced raising $2.2M We are thrilled to have the support of HPA as we prepare for the launch of Regulora,” said Tim Rudolphi, CEO of metaMe Health. “We in funding.
BrainCheck , a Houston- and Austin-based company developing cognitive healthcare software to aid physicians in detecting and managing this type of care, raised $10 million in Series B funding to expand its R&D and go-to-market capabilities as it works on new digitaltherapeutics for Alzheimer’s and related dementias.
With the recent funding, Atommerce plans to enhance artificial intelligence and machine learning technology for its platform and invest in digitaltherapeutics specialized in mental illness. The company’s AI chatbot RONI, which was launched in December, supports human professionals by providing recommended answers, Kim said. .
Alzheimer’s is the leading cause of dementia and caregivers are often overwhelmed, without enough support. Neuroglee , a Singapore-based health tech startup, wants to help with a digitaltherapeutic platform created to treat patients in the early stages of the disease. million in pre-seed funding. The round was led by Eisai Co.,
D’Ambra and Zhang previously worked in digital health spaces before deciding to found Arise, a New York–based virtual eating disorder care company. Arise is looking to provide education, care and long-term support from licensed providers and personalized care plans for those afflicted with any disordered eating.
The inaugural cohort marks an important milestone in the NJEDA’s commitment to fostering innovation and supporting business ventures in their critical early stages. By supporting these 10 new, cutting-edge companies, New Jersey is firmly cementing itself as a national leader in innovation.” million in bonus grant funding.
The Irvine-based company is looking to provide recovering heart attack and heart disease patients an at-home alternative to care with guided support over a 12-week course. “A Image Credits: Moving Analytics.
Medisafe, a leading digitaltherapeutics companion platform, today announced the immediate deployment of its new Medisafe Maestro platform. This advanced technology seamlessly orchestrates medication adherence journeys with precision and speed, creating personalized patient support resources delivered through a digital drug companion.
Medisafe, a leading digitaltherapeutics company specializing in digital companions, has been selected by UCB to develop branded digital drug companions for its epilepsy medications. Read more here.
Digitaltherapeutics companion platform Medisafe has deployed its new Maestro platform, which aims to orchestrate medication adherence journeys with precision and speed and create personalized patient support resources. Read more here.
Medisafe, a Boston, MA-based digitaltherapeutics companion platform, announced the immediate deployment of its new Medisafe Maestro platform. Read more here. The post [Medisafe in HIT Consultant] Medisafe Launches New Platform for Medication Management to Improve Patient Journey appeared first on OurCrowd Blog.
BOSTON, April 6, 2020 /PRNewswire/ — Medisafe, a leading digitaltherapeutics companion company providing medication management solutions for patients across the healthcare continuum, today announced the immediate deployment of on-demand and ongoing support for patients worldwide facing new challenges as a result of COVID-19.
startup that offers personalized digitaltherapeutics for women going through menopause, has closed a second round of funding — taking $12 million from lead investor Octopus Ventures, along with participation from U.S.-based Vira Health , a U.K. based VC firm Optum Ventures, as it gears up to hop over the pond.
Our overall focus is and has always been on central nervous system (CNS), and we are agnostic as to the modality, be it psychedelic drug development, other pharmacological approaches, medtech devices, or digitaltherapeutics. Additionally, a reliable source of information to educate individuals would be required.
MedRhythms, a Portland, Maine-based digitaltherapeutics company, is building direct stimulation, prescription therapeutics that use sensors, music, and software to improve loss of mobility caused by neurologic injuries and diseases. How does MedRhythms’ technology work?
But the longer term hope, presumably, is for Neko to gain economies of scale and be able to reduce the cost per scan — i.e. if it can make sense of all the data it hopes to obtain from paying customers and then either identify monetizable patterns itself (or partner with others willing to pay for access to support medical research etc).
While 510(k)s are the most streamlined medical device submission, PMAs are the most complicated because they’re required for any Class III product and are generally intended for medical devices supporting or sustaining human life, or which can cause grave injury. Caption Health’s Caption AI or Subtle Medical’s SubtleMR ).
Real-world results show users prefer to wait on COVID-19 vaccine dose, refer to a physician for guidance on timing, according to a new survey from Medisafe, a digitaltherapeutics platform that supports users with advanced medication management.
We organize all of the trending information in your field so you don't have to. Join 24,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content